Citations (388)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (49)
Ya-Bin Ma, Paul Chan, Yuzhen Zhang, Brian Tomlinson & Zhongmin Liu. (2019) Evaluating the efficacy and safety of atorvastatin + ezetimibe in a fixed-dose combination for the treatment of hypercholesterolemia. Expert Opinion on Pharmacotherapy 20:8, pages 917-928.
Read now
Read now
Uffe Ravnskov, Michel de Lorgeril, David M Diamond, Rokuro Hama, Tomohito Hamazaki, Björn Hammarskjöld, Niamh Hynes, Malcolm Kendrick, Peter H Langsjoen, Luca Mascitelli, Kilmer S McCully, Harumi Okuyama, Paul J Rosch, Tore Schersten, Sherif Sultan & Ralf Sundberg. (2018) LDL-C does not cause cardiovascular disease: a comprehensive review of the current literature. Expert Review of Clinical Pharmacology 11:10, pages 959-970.
Read now
Read now
Ju-Hee Lee, Sang-Hyun Kim, Dong-Ju Choi, Seung-Jea Tahk, Jung-Han Yoon, Si Wan Choi, Taek-Jong Hong & Hyo-Soo Kim. (2017) Efficacy and tolerability of two different formulations of atorvastatin in Korean patients with hypercholesterolemia: a multicenter, prospective, randomized clinical trial. Drug Design, Development and Therapy 11, pages 2277-2285.
Read now
Read now
Jesse D. Ortendahl, Amanda L. Harmon, Tanya G. K. Bentley & Michael S. Broder. (2017) A systematic literature review of methods of incorporating mortality in cost-effectiveness analyses of lipid-lowering therapies. Journal of Medical Economics 20:7, pages 767-775.
Read now
Read now
T. D. Filippatos, M. Florentin, M. Georgoula & M. S. Elisaf. (2017) Pharmacological management of diabetic dyslipidemia. Expert Review of Clinical Pharmacology 10:2, pages 187-200.
Read now
Read now
Furio Colivicchi, Catarina Sternhufvud & Sanjay K Gandhi. (2015) Impact of treatment with rosuvastatin and atorvastatin on cardiovascular outcomes: evidence from the Archimedes-simulated clinical trials. ClinicoEconomics and Outcomes Research 7, pages 555-565.
Read now
Read now
Vasilios G. Athyros, Niki Katsiki, Asterios Karagiannis & Dimitri P. Mikhailidis. (2014) Are statins ‘IDEAL’ for non-alcoholic fatty liver disease?. Current Medical Research and Opinion 30:2, pages 229-231.
Read now
Read now
Terry A. Jacobson, Debra A. Wertz, Andreas Kuznik & Mark Cziraky. (2013) Cardiovascular event rates in atorvastatin patients versus patients switching from atorvastatin to simvastatin. Current Medical Research and Opinion 29:7, pages 773-781.
Read now
Read now
Antonia Delgado-Montero & Jose L Zamorano. (2012) Atorvastatin calcium plus amlodipine for the treatment of hypertension. Expert Opinion on Pharmacotherapy 13:18, pages 2673-2685.
Read now
Read now
Michael S. Kostapanos, Moses S. Elisaf & Dimitri P. Mikhailidis. (2012) Targeting cardiovascular risk: the impact of age, gender and compliance to treatment. Current Medical Research and Opinion 28:9, pages 1415-1419.
Read now
Read now
Vasilios G Athyros, Niki Katsiki, Asterios Karagiannis & Dimitri P Mikhailidis. (2012) Stage of chronic kidney disease and severity of coronary heart disease manifestation. Expert Opinion on Pharmacotherapy 13:4, pages 457-460.
Read now
Read now
Vasilios G. Athyros, Konstantinos Tziomalos, Georgios N. Daskalopoulos, Asterios Karagiannis & Dimitri P. Mikhailidis. (2011) Statin-based treatment for cardiovascular risk and non-alcoholic fatty liver disease. Killing two birds with one stone?. Annals of Medicine 43:3, pages 167-171.
Read now
Read now
Vasilios G Athyros, Konstantinos Tziomalos, Asterios Karagiannis & Dimitri P Mikhailidis. (2010) Atorvastatin: safety and tolerability. Expert Opinion on Drug Safety 9:4, pages 667-674.
Read now
Read now
Paul N Hopkins. (2010) Encouraging appropriate treatment for familial hypercholesterolemia. Clinical Lipidology 5:3, pages 339-354.
Read now
Read now
Maurizio Paciaroni & Julien Bogousslavsky. (2009) Statins and stroke prevention. Expert Review of Cardiovascular Therapy 7:10, pages 1231-1243.
Read now
Read now
Antonio Iglesias del Sol & Prabath WB Nanayakkara. (2008) Pravastatin: an evidence-based statin?. Expert Opinion on Drug Metabolism & Toxicology 4:6, pages 821-825.
Read now
Read now
Vasilios G. Athyros, Anna I. Kakafika, Athanasios A. Papageorgiou, Kosmas I. Paraskevas, Konstantinos Tziomalos, Panagiotis Anagnostis, Efstathios Pagourelias, Charalambos Koumaras, Asterios Karagiannis & Dimitri P. Mikhailidis. (2008) Effects of statin treatment in men and women with stable coronary heart disease: a subgroup analysis of the GREACE Study. Current Medical Research and Opinion 24:6, pages 1593-1599.
Read now
Read now
Vasilios G Athyros, Anna Kakafika, Konstantinos Tziomalos, Asterios Karagiannis & Dimitri P Mikhailidis. (2008) Cholesteryl ester transfer protein inhibition and HDL increase: has the dream ended?. Expert Opinion on Investigational Drugs 17:4, pages 445-449.
Read now
Read now
Kevin A. Bybee, John H. Lee & James H. O'Keefe. (2008) Cumulative clinical trial data on atorvastatin for reducing cardiovascular events: the clinical impact of atorvastatin. Current Medical Research and Opinion 24:4, pages 1217-1229.
Read now
Read now
FD Richard Hobbs. (2007) Can combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? The single pill of amlodipine/atorvastatin. Vascular Health and Risk Management 3:5, pages 711-719.
Read now
Read now
Pierre Amarenco. (2007) Atorvastatin in prevention of stroke and transient ischaemic attack. Expert Opinion on Pharmacotherapy 8:16, pages 2789-2797.
Read now
Read now
Irene F. Gazi, Stella S. Daskalopoulou, Devaki R. Nair & Dimitri P. Mikhailidis. (2007) Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin. Current Medical Research and Opinion 23:9, pages 2183-2192.
Read now
Read now
C. Farsang, V. Athyros & A. Gaw. (2007) A multicentre, open study to assess the effect of individualizing starting doses of atorvastatin according to baseline LDL-C levels on achieving cholesterol targets: the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST-2) study. Current Medical Research and Opinion 23:8, pages 1945-1956.
Read now
Read now
Krista M. Dale, Craig I. Coleman, Sachin A. Shah, Aarti A. Patel, Jeffrey Kluger & C. Michael White. (2007) Impact of gender on statin efficacy. Current Medical Research and Opinion 23:3, pages 565-574.
Read now
Read now
Jun-ren Zhu, Brian Tomlinson, Young Moo Ro, Kui-Hian Sim, Yuan-Teh Lee & Charn Sriratanasathavorn. (2007) A randomised study comparing the efficacy and safety of rosuvastatin with atorvastatin for achieving lipid goals in clinical practice in Asian patients at high risk of cardiovascular disease (DISCOVERY-Asia study). Current Medical Research and Opinion 23:12, pages 3055-3068.
Read now
Read now
JV (Ian) Nixon. (2006) Who should receive a statin drug to lower cardiovascular risk? Does the drug and the dose of the drug matter?. Vascular Health and Risk Management 2:4, pages 441-446.
Read now
Read now
Stella S. Daskalopoulou & Dimitri P. Mikhailidis. (2006) Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe. Current Medical Research and Opinion 22:3, pages 511-528.
Read now
Read now
Francisco A. H. Fonseca, Alvaro Ruiz, Ernesto G. Cardona-Muñoz, Jose M. Silva, Nery Fuenmayor & Marcelo Marotti. (2005) The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL‐C Value – an Evaluation of Rosuvastatin therapY compared with atorvastatin. Current Medical Research and Opinion 21:8, pages 1307-1315.
Read now
Read now
Sander I van Leuven & John JP Kastelein. (2005) Atorvastatin. Expert Opinion on Pharmacotherapy 6:7, pages 1191-1203.
Read now
Read now
J. D. Lee, J. R. Morrissey, D. P. Mikhailidis & V. Patel. (2005) CARDS on the table: should everybody with type 2 diabetes take a statin?. Current Medical Research and Opinion 21:3, pages 357-361.
Read now
Read now
Vasilios G. Athyros, Dimitri P. Mikhailidis, Athanasios A. Papageorgiou, Vasilios I. Bouloukos, Anthimos N. Pehlivanidis, Athanasios N. Symeonidis, Anna I. Kakafika, Stella S. Daskalopoulou & Moses Elisaf. (2005) Effect of statins and aspirin alone and in combination on clinical outcome in dyslipidaemic patients with coronary heart disease. A subgroup analysis of the GREACE study. Platelets 16:2, pages 65-71.
Read now
Read now
Anthony S. Wierzbicki. (2005) Have we forgotten the pivotal role of high-density lipoprotein cholesterol in atherosclerosis prevention?. Current Medical Research and Opinion 21:2, pages 299-305.
Read now
Read now
Mehmet Kanbay, Aylin Yildirir, Hüseyin Bozbas, Taner Ulus, Muhammet Bilgi, Haldun Muderrisoglu, Ali Akcay & Fatma Nurhan Ozdemir. (2005) Statin Therapy Helps to Control Blood Pressure Levels in Hypertensive Dyslipidemic Patients. Renal Failure 27:3, pages 297-303.
Read now
Read now
Christopher J Boos & Gregory YH Lip. (2004) Novel therapies for the prevention of stroke. Expert Opinion on Investigational Drugs 13:12, pages 1615-1630.
Read now
Read now
Anthony S Wierzbicki. (2004) Lipid-lowering therapies in development. Expert Opinion on Investigational Drugs 13:11, pages 1405-1418.
Read now
Read now
Vasilios G. Athyros, Dimitri P. Mikhailidis, Athanasios A. Papageorgiou, Triandafillos P. Didangelos, Emmanuel S. Ganotakis, Athanasios N. Symeonidis, Stella S. Daskalopoulou, Anna I. Kakafika & Moses Elisaf. (2004) Prevalence of atherosclerotic vascular disease among subjects with the metabolic syndrome with or without diabetes mellitus: the METS-GREECE Multicentre Study. Current Medical Research and Opinion 20:11, pages 1691-1701.
Read now
Read now
Vasilios G. Athyros, Dimitri P. Mikhailidis, Athanasios A. Papageorgiou, Athanasios N. Symeonidis, Stella S. Daskalopoulou, Anna I. Kakafika, Anthimos N. Pehlivanidis, Vasilios I. Bouloukos & Anatoly Langer. (2004) Relationship between LDL-C and non-HDL-C levels and clinical outcome in the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Current Medical Research and Opinion 20:9, pages 1385-1392.
Read now
Read now
T. P. Didangelos, A. K. Thanopoulou, S. H. Bousboulas, C. L. Sambanis, V. G. Athyros, E. A. Spanou, K. C. Dimitriou, S. I. Pappas, B. G. Karamanos & D. T. Karamitsos. (2004) The ORlistat and CArdiovascular risk profile in patients with metabolic syndrome and type 2 DIAbetes (ORliCARDIA) study. Current Medical Research and Opinion 20:9, pages 1393-1401.
Read now
Read now
J. D. Lee, J. R. Morrissey & V. Patel. (2004) Recalculation of cardiovascular risk score as a surrogate marker of change in clinical care of diabetes patients: the Alphabet POEM project (Practice Of Evidence-based Medicine). Current Medical Research and Opinion 20:5, pages 765-772.
Read now
Read now
Vasilios G. Athyros, Dimitri P. Mikhailidis, Athanasios A. Papageorgiou, Athanasios N. Symeonidis, Bodosakis R. Mercouris, Anthimos N. Pehlivanidis, Vasilios I. Bouloukos & Moses Elisaf. (2004) Effect of atorvastatin on highdensity lipoprotein cholesteroland its relationship withcoronary events: a subgroupanalysis of the GREekAtorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. Current Medical Research and Opinion 20:5, pages 627-637.
Read now
Read now
Anthony S Wierzbicki. (2003) New lipid-lowering agents. Expert Opinion on Emerging Drugs 8:2, pages 365-376.
Read now
Read now
Serena Tonstad. (2003) Treatment of children with familial hypercholesterolemia. Expert Review of Cardiovascular Therapy 1:1, pages 135-141.
Read now
Read now
Vasilios G. Athyros, Athanasios A. Papageorgiou, Moses Elisaf & Dimitri P. Mikhailidis. (2003) Statins and renal function in patients with diabetes mellitus. Current Medical Research and Opinion 19:7, pages 615-617.
Read now
Read now
Stavroula Tsiara, Moses Elisaf & Dimitri P. Mikhailidis. (2003) Early vascular benefits of statin therapy. Current Medical Research and Opinion 19:6, pages 540-556.
Read now
Read now
Ilgın Karaca, Erdogan ilkay, Mehmet Akbulut, Mustafa Yavuzkır, Murat Pekdemir, Handan Akbulut & Nadi Arslan. (2003) Atorvastatin affects C-reactive protein levels in patients with coronary artery disease. Current Medical Research and Opinion 19:3, pages 187-191.
Read now
Read now
A. S. Wierzbicki, D. P. Mikhailidis, R. Wray, M. Schachter, R. Cramb, W. G. Simpson & C. B. Byrne. (2003) Statin-fibrate combination therapy for hyperlipidaemia: a review. Current Medical Research and Opinion 19:3, pages 155-168.
Read now
Read now
Athanasios G. Kontopoulos, Vasilios G. Athyros, Anthimos N. Pehlivanidis, Dimokritos S. Demitriadis, Athanasios A. Papageorgiou & Harisios Boudoulas. (2003) Long-term treatment effect of atorvastatin on aortic stiffness in hypercholesterolaemic patients. Current Medical Research and Opinion 19:1, pages 22-27.
Read now
Read now
Vasilios G. Athyros, Dimitri P. Mikhailidis, Athanasios A. Papageorgiou, Bodosakis R. Mercouris, Valasia V. Athyrou, Athanasios N. Symeonidis, Elias O. Basayannis, Dimokritos S. Demitriadis & Athanasios G. Kontopoulos. (2002) Attaining United Kingdom-European Atherosclerosis Society Low-density Lipoprotein Cholesterol Guideline Target Values in the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. Current Medical Research and Opinion 18:8, pages 499-502.
Read now
Read now
Kathy Ann LaCivita & Gustavo Villarreal. (2002) Differences in Lipid Profiles of Patients Given Rosiglitazone Followed by Pioglitazone. Current Medical Research and Opinion 18:6, pages 363-370.
Read now
Read now
Articles from other publishers (339)
Xinghua Bai, Jun Jiang, Sijia Tu & Weizong Zhang. (2023) Hydrogels Loaded with Atorvastatin‐Metal Organic Framework Have a Preventive Effect on Coronary Heart Disease. Chemistry & Biodiversity.
Crossref
Crossref
Oluwabunmi Ogungbe, Jelani K. Grant, Adeoluwa Segilola Ayoola, Eyram Bansah, Hailey N. Miller, Timothy B. Plante, Payam Sheikhattari, Yvonne Commodore-Mensah, Ruth-Alma N. Turkson-Ocran, Stephen P. Juraschek, Seth S. Martin, Michael Lin, Cheryl R. Himmelfarb & Erin D. Michos. (2023) Strategies for Improving Enrollment of Diverse Populations with a Focus on Lipid-Lowering Clinical Trials. Current Cardiology Reports 25:10, pages 1189-1210.
Crossref
Crossref
Jaehoon Chung, Hack-Lyoung Kim, Woo-Hyun Lim, Jae-Bing Seo, Joo-Heeg Zo, Myung-A Kim & Sang-Hyun Kim. (2023) New onset diabetes mellitus and cardiovascular outcomes according to statin intensity in patients after drug-eluting stent implantation in Asian patients. Scientific Reports 13:1.
Crossref
Crossref
Gregory J. Dehmer, Cindy L. Grines, Faisal G. Bakaeen, Dorian L. Beasley, Theresa M. Beckie, Jack Boyd, Joaquin E. Cigarroa, Sandeep R. Das, Rebecca L. Diekemper, Jennifer Frampton, Connie N. Hess, Nkechinyere Ijioma, Jennifer S. Lawton, Binita Shah & Nadia R. Sutton. (2023) 2023 AHA/ACC Clinical Performance and Quality Measures for Coronary Artery Revascularization. Journal of the American College of Cardiology 82:11, pages 1131-1174.
Crossref
Crossref
A. González-Domínguez, A. Durán, Á. Hidalgo-Vega & V. Barrios. (2023) Cost-effectiveness of the CNIC-Polypill versus separate monocomponents in cardiovascular secondary prevention in Spain. Revista Clínica Española (English Edition) 223:7, pages 414-422.
Crossref
Crossref
A. González-Domínguez, A. Durán, A. Hidalgo-Vega & V. Barrios. (2023) Coste-efectividad de la polipíldora CNIC frente a los monocomponentes separados en prevención secundaria cardiovascular en España. Revista Clínica Española 223:7, pages 414-422.
Crossref
Crossref
M. V. Ezhov, V. V. Kukharchuk, I. V. Sergienko, A. S. Alieva, M. B. Antsiferov, A. A. Ansheles, G. G. Arabidze, D. M. Aronov, G. P. Arutyunov, N. M. Akhmedzhanov, T. V. Balakhonova, O. L. Barbarash, S. A. Boytsov, M. G. Bubnova, M. I. Voevoda, G. R. Galstyan, A. S. Galyavich, N. B. Gornyakova, V. S. Gurevich, I. I. Dedov, O. M. Drapkina, D. V. Duplyakov, S. Ya. Eregin, A. I. Ershova, O. B. Irtyuga, R. S. Karpov, Yu. A. Karpov, M. A. Kachkovsky, Zh. D. Kobalava, N. A. Koziolova, G. A. Konovalov, V. O. Konstantinov, E. D. Kosmacheva, Yu. V. Kotovskaya, A. I. Martynov, A. N. Meshkov, D. V. Nebieridze, S. V. Nedogoda, A. G. Obrezan, V. E. Oleinikov, S. N. Pokrovsky, Yu. I. Ragino, O. P. Rotar, V. V. Skibitsky, O. G. Smolenskaya, A. A. Sokolov, A. B. Sumarokov, E. Filippov, Yu. Sh. Halimov, I. E. Chazova, I. I. Shaposhnik, M. V. Shestakova, S. S. Yakushin & E. V. Shlyakhto. (2023) Disorders of lipid metabolism. Clinical Guidelines 2023. Russian Journal of Cardiology 28:5, pages 5471.
Crossref
Crossref
Chin-Huan Chang, Shu-Tin Yeh, Seng-Wei Ooi, Chung-Yi Li & Hua-Fen Chen. (2023) The relationship of low-density lipoprotein cholesterol and all-cause or cardiovascular mortality in patients with type 2 diabetes: a retrospective study. PeerJ 11, pages e14609.
Crossref
Crossref
Martina Aeschbacher‐Germann, Nathalie Kaiser, Alexandre Speierer, Manuel R. Blum, Douglas C. Bauer, Cinzia Del Giovane, Drahomir Aujesky, Baris Gencer, Nicolas Rodondi & Elisavet Moutzouri. (2023) Lipid‐Lowering Trials Are Not Representative of Patients Managed in Clinical Practice: A Systematic Review and Meta‐Analysis of Exclusion Criteria. Journal of the American Heart Association 12:1.
Crossref
Crossref
Pierre Vladimir Ennezat, Raphaëlle-Ashley Guerbaai, Sylvestre Maréchaux, Thierry H. Le Jemtel & Patrice François. (2023) Extent of Low-density Lipoprotein Cholesterol Reduction and All-cause and Cardiovascular Mortality Benefit: A Systematic Review and Meta-analysis. Journal of Cardiovascular Pharmacology 81:1, pages 35-44.
Crossref
Crossref
S. P. Radhoe, E. Boersma, M. Bertrand, W. Remme, R. Ferrari, K. Fox, S. MacMahon, J. Chalmers, M. L. Simoons & J. J. Brugts. (2022) The Effects of a Perindopril-Based Regimen in Relation to Statin Use on the Outcomes of Patients with Vascular Disease: a Combined Analysis of the ADVANCE, EUROPA, and PROGRESS Trials. Cardiovascular Drugs and Therapy.
Crossref
Crossref
Sana Rashid, Giselle Alexandra Suero-Abreu, Maciej Tysarowski, Hyo-bin Um, Kajol Shah, Yawen Zhang, Analise Douglas & Daniel Matassa. (2022) Increasing statin prescription rates to prevent cardiovascular disease among high-risk populations: a quality improvement intervention centred on a novel interactive tool. BMJ Open Quality 11:3, pages e001947.
Crossref
Crossref
T. V. Gorokhova & N. B. Perepech. (2022) Potential of combination therapy in patients with hypertension and dyslipidemia. Russian Journal of Cardiology 27:7, pages 5132.
Crossref
Crossref
Ibrahim Yildiz, Ibrahim Rencüzoğulları, Yavuz Karabağ, Muammer Karakayali, Inanc Artac & Mehmet Sait Gurevin. (2022) Predictors of left ventricular ejection function decline in young patients with ST-segment elevation myocardial infarction. Revista da Associação Médica Brasileira 68:6, pages 802-807.
Crossref
Crossref
Robert DuBroff, Aseem Malhotra & Michel de Lorgeril. (2021) Hit or miss: the new cholesterol targets. BMJ Evidence-Based Medicine 26:6, pages 271-278.
Crossref
Crossref
Wenrui Ma, Qinyuan Pan, Defeng Pan, Tongda Xu, Hong Zhu & Dongye Li. (2021) Efficacy and Safety of Lipid-Lowering Drugs of Different Intensity on Clinical Outcomes: A Systematic Review and Network Meta-Analysis. Frontiers in Pharmacology 12.
Crossref
Crossref
Georgios Sfikas, Michael Psallas, Charalambos Koumaras, Konstantinos Imprialos, Evangelos Perdikakis, Michael Doumas, Olga Giouleme, Asterios Karagiannis & Vasilios G. Athyros. (2021) Prevalence, Diagnosis, and Treatment with 3 Different Statins of Non-alcoholic Fatty Liver Disease/Non-alcoholic Steatohepatitis in Military Personnel. Do Genetics Play a Role?. Current Vascular Pharmacology 19:5, pages 572-581.
Crossref
Crossref
Dahae Lee, Ji-Youn Kim, Hae-Won Kim, Jeong-Eun Yoo & Ki Sung Kang. (2021) Combined Beneficial Effect of Genistein and Atorvastatin on Adipogenesis in 3T3-L1 Adipocytes. Biomolecules 11:7, pages 1052.
Crossref
Crossref
José Carlos Nicolau, Gilson Soares FeitosaFilhoFilho, João Luiz Petriz, Remo Holanda de Mendonça Furtado, Dalton Bertolim Précoma, Walmor Lemke, Renato Delascio Lopes, Ari Timerman, José A. MarinNetoNeto, Luiz BezerraNetoNeto, Bruno Ferraz de Oliveira Gomes, Eduardo Cavalcanti Lapa Santos, Leopoldo Soares Piegas, Alexandre de Matos Soeiro, Alexandre Jorge de Andrade Negri, Andre Franci, Brivaldo MarkmanFilhoFilho, Bruno Mendonça Baccaro, Carlos Eduardo Lucena Montenegro, Carlos Eduardo Rochitte, Carlos José Dornas Gonçalves Barbosa, Cláudio Marcelo Bittencourt das Virgens, Edson Stefanini, Euler Roberto Fernandes Manenti, Felipe Gallego Lima, Francisco das Chagas MonteiroJúniorJúnior, Harry CorreaFilhoFilho, Henrique Patrus Mundim Pena, Ibraim Masciarelli Francisco Pinto, João Luiz de Alencar Araripe Falcão, Joberto Pinheiro Sena, José Maria Peixoto, Juliana Ascenção de Souza, Leonardo Sara da Silva, Lilia Nigro Maia, Louis Nakayama Ohe, Luciano Moreira Baracioli, Luís Alberto de Oliveira Dallan, Luis Augusto Palma Dallan, Luiz Alberto Piva e Mattos, Luiz Carlos Bodanese, Luiz Eduardo Fonteles Ritt, Manoel Fernandes Canesin, Marcelo Bueno da Silva Rivas, Marcelo Franken, Marcos José Gomes Magalhães, Múcio Tavares de OliveiraJúniorJúnior, Nivaldo Menezes FilgueirasFilhoFilho, Oscar Pereira Dutra, Otávio Rizzi Coelho, Paulo Ernesto Leães, Paulo Roberto Ferreira Rossi, Paulo Rogério Soares, Pedro Alves LemosNetoNeto, Pedro Silvio Farsky, Rafael Rebêlo C. Cavalcanti, Renato Jorge Alves, Renato Abdala Karam Kalil, Roberto Esporcatte, Roberto Luiz Marino, Roberto Rocha Corrêa Veiga Giraldez, Romeu Sérgio Meneghelo, Ronaldo de Souza Leão Lima, Rui Fernando Ramos, Sandra Nivea dos Reis Saraiva Falcão, Talia Falcão Dalçóquio, Viviana de Mello Guzzo Lemke, William Azem Chalela & Wilson MathiasJúniorJúnior. (2021) Diretrizes da Sociedade Brasileira de Cardiologia sobre Angina Instável e Infarto Agudo do Miocárdio sem Supradesnível do Segmento ST – 2021. Arquivos Brasileiros de Cardiologia 117:1, pages 181-264.
Crossref
Crossref
Silvie Rimpelová, Michal Kolář, Hynek Strnad, Tomáš Ruml, Libor Vítek & Helena Gbelcová. (2021) Comparison of Transcriptomic Profiles of MiaPaCa-2 Pancreatic Cancer Cells Treated with Different Statins. Molecules 26:12, pages 3528.
Crossref
Crossref
Vasilios Gabriel Athyros. (2021) Multifactorial treatment of diabetic patients with cardiovascular disease to maximize results. Journal of Diabetes and its Complications 35:6, pages 107904.
Crossref
Crossref
J. Masjuan, J. Gállego, J.M. Aguilera, J.F. Arenillas, M. Castellanos, F. Díaz, J.C. Portilla & F. Purroy. (2021) Use of cardiovascular polypills for the secondary prevention of cerebrovascular disease. Neurología (English Edition) 36:1, pages 1-8.
Crossref
Crossref
J. Masjuan, J. Gállego, J.M. Aguilera, J.F. Arenillas, M. Castellanos, F. Díaz, J.C. Portilla & F. Purroy. (2021) Uso de la polipíldora cardiovascular en la prevención secundaria de la enfermedad cerebrovascular. Neurología 36:1, pages 1-8.
Crossref
Crossref
Nazanin Rajai & Francine K. Welty. 2021. Stroke Revisited: Dyslipidemia in Stroke. Stroke Revisited: Dyslipidemia in Stroke
173
202
.
Victoria Ros-Castelló, Elena Natera-Villalba, Ana Gómez-López, Arantxa Sánchez-Sánchez, Juan Luis Chico-García, Sebastian García-Madrona, Rocio Vera-Lechuga, Consuelo Matute-Lozano, Alicia de Felipe Mimbrera, Antonio Cruz-Culebras, Araceli Alonso-Canovas & Jaime Masjuan. (2020) Use of the Cardiovascular Polypill in Secondary Prevention of Cerebrovascular Disease: A Real-Life Tertiary Hospital Cohort Study of 104 Patients. Cerebrovascular Diseases Extra 10:3, pages 166-173.
Crossref
Crossref
Z. D. KobalavaE. V. Kokhan. (2020) Hypertension and Hypercholesterolemia: is it Time for Anti-«Lipitensive» Therapy?. Rational Pharmacotherapy in Cardiology 16:5, pages 842-851.
Crossref
Crossref
Jeongseon Kim, Tung Hoang, Ji-Myung Kim, So Young Bu, Jeong-Hwa Choi, Eunju Park, Seung-Min Lee, Eunmi Park, Ji Yeon Min, In Seok Lee, So Young Youn & Jee-Young Yeon. (2020) All-Cause Mortality and Cardiovascular Death between Statins and Omega-3 Supplementation: A Meta-Analysis and Network Meta-Analysis from 55 Randomized Controlled Trials. Nutrients 12:10, pages 3203.
Crossref
Crossref
Irfan Khan, Eric D. Peterson, Christopher P. Cannon, Lauren E. Sedita, Jay M. Edelberg & Kausik K. Ray. (2020) Time‐Dependent Cardiovascular Treatment Benefit Model for Lipid‐Lowering Therapies. Journal of the American Heart Association 9:15.
Crossref
Crossref
Tung Hoang & Jeongseon Kim. (2020) Comparative Effect of Statins and Omega-3 Supplementation on Cardiovascular Events: Meta-Analysis and Network Meta-Analysis of 63 Randomized Controlled Trials Including 264,516 Participants. Nutrients 12:8, pages 2218.
Crossref
Crossref
V. V. Kukharchuk, M. V. Ezhov, I. V. Sergienko, G. G. Arabidze, T. V. Balakhonova, V. S. Gurevich, P. A. Zelveyan, T. M. Murataliev, G. Sh. Myrzakhmetova, O. A. Sudzhaeva, A. B. Shek, V. A. Azizov, N. B. Gornyakova, M. A. Kachkovsky, P. P. Malyshev, S. N. Pokrovsky, A. A. Sokolov, A. B. Sumarokov, A. G. Obrezan, I. I. Shaposhnik, M. B. Antsiferov, A. A. Ansheles, D. M. Aronov, N. M. Akhmedzhanov, O. L. Barbarash, S. A. Boytsov, M. G. Bubnova, M. I. Voevoda, G. R. Galstyan, A. S. Galyavich, O. M. Drapkina, D. V. Duplyakov, S. Ya. Eregin, R. S. Karpov, Yu. A. Karpov, N. A. Koziolova, G. A. Konovalov, V. O. Konstantinov, E. D. Kosmacheva, S. V. Nedogoda, V. E. Olejnikov, Yu. I. Ragino, V. V. Skibickij, O. G. Smolenskaya, Yu. Sh. Halimov, I. E. Chazova, A. E. Filippov, M. V. Shestakova & S. S. Yakushin. (2020) EURASIAN ASSOCIATION OF CARDIOLOGY (EAC)/ RUSSIAN NATIONAL ATHEROSCLEROSIS SOCIETY (RNAS, RUSSIA) GUIDELINES FOR THE DIAGNOSIS AND CORRECTION OF DYSLIPIDEMIA FOR THE PREVENTION AND TREATMENT OF ATHEROSCLEROSIS (2020). Eurasian heart journal:2, pages 6-29.
Crossref
Crossref
John B. Kostis, Michail Giakoumis, Stavros Zinonos, Javier Cabrera & William J. Kostis. (2020) Meta-Analysis of Usefulness of Treatment of Hypercholesterolemia With Statins for Primary Prevention in Patients Older Than 75 Years. The American Journal of Cardiology 125:8, pages 1154-1157.
Crossref
Crossref
Safi U. Khan & Erin D. Michos. (2020) Cardiovascular mortality after intensive LDL-Cholesterol lowering: Does baseline LDL-Cholesterol really matter?. American Journal of Preventive Cardiology 1, pages 100013.
Crossref
Crossref
Nelson Wang, Jordan Fulcher, Nishan Abeysuriya, Laura Park, Shejil Kumar, Gian Luca Di Tanna, Ian Wilcox, Anthony Keech, Anthony Rodgers & Sean Lal. (2020) Intensive LDL cholesterol-lowering treatment beyond current recommendations for the prevention of major vascular events: a systematic review and meta-analysis of randomised trials including 327 037 participants. The Lancet Diabetes & Endocrinology 8:1, pages 36-49.
Crossref
Crossref
Konstantinos Aznaouridis, Constantina Masoura, Charalambos Vlachopoulos & Dimitris Tousoulis. (2019) Statins in Stroke. Current Medicinal Chemistry 26:33, pages 6174-6185.
Crossref
Crossref
H -C Lin, J -R Lin, W -C Tsai, C -H Lu, W -N Chang, C -C Huang, H -C Wang, C -T Kung, C -M Su, Y -J Su, W -C Lin, B -C Cheng, C -W Hsu, Y -R Lai & N -W Tsai. (2019) The outcomes of statin therapy in patients with acute ischemic stroke in Taiwan: a nationwide epidemiologic study. QJM: An International Journal of Medicine 112:12, pages 891-899.
Crossref
Crossref
Kathryn S Taylor, Julie Mclellan, Jan Y Verbakel, Jeffrey K Aronson, Daniel S Lasserson, Nicola Pidduck, Nia Roberts, Susannah Fleming, Christopher A O'Callaghan, Clare R Bankhead, Amitava Banerjee, FD Richard Hobbs & Rafael Perera. (2019) Effects of antihypertensives, lipid-modifying drugs, glycaemic control drugs and sodium bicarbonate on the progression of stages 3 and 4 chronic kidney disease in adults: a systematic review and meta-analysis. BMJ Open 9:9, pages e030596.
Crossref
Crossref
Walter Masson, Martín Lobo, Daniel Siniawski, Graciela Molinero, Melina Huerín & Juan Patricio Nogueira. (2019) Impact of Lipid-Lowering Therapy on Mortality According to the Baseline Non-HDL Cholesterol Level: A Meta-Analysis. High Blood Pressure & Cardiovascular Prevention 26:4, pages 263-272.
Crossref
Crossref
Safi U. Khan, Haris Riaz, Hammad Rahman, Muhammad U. Khan, Muhammad Shahzeb Khan, Mohamad Alkhouli, Edo Kaluski, Thorsten M. Leucker & Michael J. Blaha. (2019) Association of baseline LDL-C with total and cardiovascular mortality in patients using proprotein convertase subtilisin-kexin type 9 inhibitors: A systematic review and meta-analysis. Journal of Clinical Lipidology 13:4, pages 538-549.
Crossref
Crossref
Scott M. GrundyNeil J. StoneAlison L. BaileyCraig BeamKim K. BirtcherRoger S. BlumenthalLynne T. BraunSarah de FerrantiJoseph Faiella-TommasinoDaniel E. FormanRonald GoldbergPaul A. HeidenreichMark A. HlatkyDaniel W. JonesDonald Lloyd-JonesNuria Lopez-PajaresChiadi E. NdumeleCarl E. OrringerCarmen A. PeraltaJoseph J. SaseenSidney C. SmithJrJrLaurence SperlingSalim S. ViraniJoseph Yeboah. (2019) 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 139:25.
Crossref
Crossref
Scott M. GrundyNeil J. StoneAlison L. BaileyCraig BeamKim K. BirtcherRoger S. BlumenthalLynne T. BraunSarah de FerrantiJoseph Faiella-TommasinoDaniel E. FormanRonald GoldbergPaul A. HeidenreichMark A. HlatkyDaniel W. JonesDonald Lloyd-JonesNuria Lopez-PajaresChiadi E. NdumeleCarl E. OrringerCarmen A. PeraltaJoseph J. SaseenSidney C. SmithJrJrLaurence SperlingSalim S. ViraniJoseph Yeboah. (2019) 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 139:25.
Crossref
Crossref
Conor Judge, Sarah Ruttledge, Maria Costello, Robert Murphy, Elaine Loughlin, Alberto Alvarez-Iglesias, John Ferguson, Sarah Gorey, Aoife Nolan, Michelle Canavan, Martin O'Halloran & Martin J. O'Donnell. (2019) Lipid Lowering Therapy, Low-Density Lipoprotein Level and Risk of Intracerebral Hemorrhage – A Meta-Analysis. Journal of Stroke and Cerebrovascular Diseases 28:6, pages 1703-1709.
Crossref
Crossref
Scott M. Grundy, Neil J. Stone, Alison L. Bailey, Craig Beam, Kim K. Birtcher, Roger S. Blumenthal, Lynne T. Braun, Sarah de Ferranti, Joseph Faiella-Tommasino, Daniel E. Forman, Ronald Goldberg, Paul A. Heidenreich, Mark A. Hlatky, Daniel W. Jones, Donald Lloyd-Jones, Nuria Lopez-Pajares, Chiadi E. Ndumele, Carl E. Orringer, Carmen A. Peralta, Joseph J. Saseen, Sidney C. SmithJr.Jr., Laurence Sperling, Salim S. Virani & Joseph Yeboah. (2019) 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. Journal of the American College of Cardiology 73:24, pages e285-e350.
Crossref
Crossref
Scott M. Grundy, Neil J. Stone, Alison L. Bailey, Craig Beam, Kim K. Birtcher, Roger S. Blumenthal, Lynne T. Braun, Sarah de Ferranti, Joseph Faiella-Tommasino, Daniel E. Forman, Ronald Goldberg, Paul A. Heidenreich, Mark A. Hlatky, Daniel W. Jones, Donald Lloyd-Jones, Nuria Lopez-Pajares, Chiadi E. Ndumele, Carl E. Orringer, Carmen A. Peralta, Joseph J. Saseen, Sidney C. SmithJr.Jr., Laurence Sperling, Salim S. Virani & Joseph Yeboah. (2019) 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary. Journal of the American College of Cardiology 73:24, pages 3168-3209.
Crossref
Crossref
Xiaoming Jia, Mahmoud Al Rifai, Yochai Birnbaum, Sidney C. SmithJrJr & Salim S. Virani. (2019) The 2018 Cholesterol Management Guidelines: Topics in Secondary ASCVD Prevention Clinicians Need to Know. Current Atherosclerosis Reports 21:6.
Crossref
Crossref
Safi U. Khan, Hammad Rahman, Victor Okunrintemi, Haris Riaz, Muhammad Shahzeb Khan, Sudhakar Sattur, Edo Kaluski, A. Michael Lincoff, Seth S. Martin & Michael J. Blaha. (2019) Association of Lowering Low‐Density Lipoprotein Cholesterol With Contemporary Lipid‐Lowering Therapies and Risk of Diabetes Mellitus: A Systematic Review and Meta‐Analysis. Journal of the American Heart Association 8:7.
Crossref
Crossref
Luanluan Sun, Robert Clarke, Derrick Bennett, Yu Guo, Robin G. Walters, Michael Hill, Sarah Parish, Iona Y. Millwood, Zheng Bian, Yiping Chen, Canqing Yu, Jun Lv, Rory Collins, Junshi Chen, Richard Peto, Liming Li & Zhengming Chen. (2019) Causal associations of blood lipids with risk of ischemic stroke and intracerebral hemorrhage in Chinese adults. Nature Medicine 25:4, pages 569-574.
Crossref
Crossref
Jane Armitage, Colin Baigent, Elizabeth Barnes, D John Betteridge, Lisa Blackwell, Michael Blazing, Louise Bowman, Eugene Braunwald, Robert Byington, Christopher Cannon, Michael Clearfield, Helen Colhoun, Rory Collins, Björn Dahlöf, Kelly Davies, Barry Davis, James de Lemos, John R Downs, Paul Durrington, Jonathan Emberson, Bengt Fellström, Marcus Flather, Ian Ford, Maria Grazia Franzosi, Jordan Fulcher, John Fuller, Curt Furberg, David Gordon, Shinya Goto, Antonio Gotto, Heather Halls, Charlie Harper, C Morton Hawkins, Will Herrington, Graham Hitman, Hallvard Holdaas, Lisa Holland, Alan Jardine, J Wouter Jukema, John Kastelein, Sharon Kean, Anthony Keech, Adrienne Kirby, John Kjekshus, Genell Knatterud (deceased)Robert Knopp (deceased)Wolfgang Koenig, Michael Koren, Vera Krane, Martin J Landray, John LaRosa, Eva Lonn, Peter MacFarlane, Stephen MacMahon, Aldo Maggioni, Roberto Marchioli, Ian Marschner, Borislava Mihaylova, Lemuel Moyé, Sabina Murphy, Haruo Nakamura, Andrew Neil, Connie Newman, Rachel O'Connell, Chris Packard, Sarah Parish, Terje Pedersen, Richard Peto, Marc Pfeffer, Neil Poulter, David Preiss, Christina Reith, Paul Ridker, Michele Robertson, Frank Sacks, Naveed Sattar, Roland Schmieder, Patrick Serruys, Peter Sever, John Shaw, Charles Shear, John Simes, Peter Sleight, Enti Spata, Luigi Tavazzi, Jonathan Tobert, Gianni Tognoni, Andrew Tonkin, Stella Trompet, John Varigos, Christoph Wanner, Hans Wedel, Harvey White, John Wikstrand, Lars Wilhelmsen, Kate Wilson, Robin Young, Salim Yusuf & Faiez Zannad. (2019) Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. The Lancet 393:10170, pages 407-415.
Crossref
Crossref
Sherif Sultan, Ashwini D'Souza, Ioannis Zabetakis, Ronan Lordan, Alexandros Tsoupras, Edel P. Kavanagh & Niamh Hynes. 2019. The Impact of Nutrition and Statins on Cardiovascular Diseases. The Impact of Nutrition and Statins on Cardiovascular Diseases
171
200
.
Handrean Soran, Safwaan Adam & Paul N. Durrington. (2018) Optimising treatment of hyperlipidaemia: Quantitative evaluation of UK, USA and European guidelines taking account of both LDL cholesterol levels and cardiovascular disease risk. Atherosclerosis 278, pages 135-142.
Crossref
Crossref
Hideki Mochizuki, Chi-Jing Choong & Eliezer Masliah. (2018) A refined concept: α-synuclein dysregulation disease. Neurochemistry International 119, pages 84-96.
Crossref
Crossref
. (2018) The First Sign of an Impending Disaster? Headache in a Patient with Severe Hypertriglyceridemia - the Need for Preventive Plasmapheresis. Journal of Clinical Review & Case Reports 3:6.
Crossref
Crossref
Naina Mohamed Pakkir Maideen, Gobinath Manavalan & Kumar Balasubramanian. (2018) Drug interactions of meglitinide antidiabetics involving CYP enzymes and OATP1B1 transporter. Therapeutic Advances in Endocrinology and Metabolism 9:8, pages 259-268.
Crossref
Crossref
O. V. Gaisenok, A. N. Rozhkov & A. S. Lishuta. (2018) HYPOLIPIDEMIC THERAPY IN STROKE PREVENTION: EXISTING STANDARDS, EVIDENCE-BASED MEDICINE DATA AND REAL PRACTICE. Rational Pharmacotherapy in Cardiology 14:3, pages 434-440.
Crossref
Crossref
A. Agarwala, S. Kulkarni & T. Maddox. (2018) The Association of Statin Therapy with Incident Diabetes: Evidence, Mechanisms, and Recommendations. Current Cardiology Reports 20:7.
Crossref
Crossref
Stefan Weisshaar & Markus Zeitlinger. (2018) Vaccines Targeting PCSK9: A Promising Alternative to Passive Immunization with Monoclonal Antibodies in the Management of Hyperlipidaemia?. Drugs 78:8, pages 799-808.
Crossref
Crossref
Eliano P. Navarese, Jennifer G. Robinson, Mariusz Kowalewski, Michalina Kolodziejczak, Felicita Andreotti, Kevin Bliden, Udaya Tantry, Jacek Kubica, Paolo Raggi & Paul A. Gurbel. (2018) Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering. JAMA 319:15, pages 1566.
Crossref
Crossref
Konstantinos C Koskinas, George C M Siontis, Raffaele Piccolo, Dimitris Mavridis, Lorenz Räber, François Mach & Stephan Windecker. (2018) Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials. European Heart Journal 39:14, pages 1172-1180.
Crossref
Crossref
Goodarz Danaei, Luis Alberto García Rodríguez, Oscar Fernández Cantero, Roger W. Logan & Miguel A. Hernán. (2018) Electronic medical records can be used to emulate target trials of sustained treatment strategies. Journal of Clinical Epidemiology 96, pages 12-22.
Crossref
Crossref
Andromachi Reklou, Michael Doumas, Konstantinos Imprialos, Konstantinos Stavropoulos, Dimitris Patoulias & Vasilios G. Athyros. (2018) Reduction of Vascular Inflammation, LDL-C, or Both for the Protection from Cardiovascular Events?. The Open Cardiovascular Medicine Journal 12:1, pages 29-40.
Crossref
Crossref
Yinhui Liu, Xiaobo Song, Huimin Zhou, Xue Zhou, Yunlong Xia, Xin Dong, Wei Zhong, Shaoying Tang, Lili Wang, Shu Wen, Jing Xiao & Li Tang. (2018) Gut Microbiome Associates With Lipid-Lowering Effect of Rosuvastatin in Vivo. Frontiers in Microbiology 9.
Crossref
Crossref
Handrean Soran, See Kwok, Safwaan Adam, Jan Hoong Ho & Paul N. Durrington. (2017) Evidence for more intensive cholesterol lowering. Current Opinion in Lipidology 28:4, pages 291-299.
Crossref
Crossref
Benjamin Burggraaf & Manuel Castro Cabezas. (2017) Interventions in type 2 diabetes mellitus and cardiovascular mortality–An overview of clinical trials. European Journal of Internal Medicine 42, pages 1-15.
Crossref
Crossref
Paul S. Jellinger, Yehuda Handelsman, Paul D. Rosenblit, Zachary T. Bloomgarden, Vivian A. Fonseca, Alan J. Garber, George Grunberger, Chris K. Guerin, David S.H. Bell, Jeffrey I. Mechanick, Rachel Pessah-Pollack, Kathleen Wyne, Donald Smith, Eliot A. Brinton, Sergio Fazio, Michael Davidson, Paul S. Jellinger, Yehuda Handelsman, David S.H. Bell, Zachary T. Bloomgarden, Eliot A. Brinton, Michael H. Davidson, Sergio Fazio, Vivian A. Fonseca, Alan J. Garber, George Grunberger, Chris K. Guerin, Jeffrey I. Mechanick, Rachel Pessah-Pollack, Paul D. Rosenblit, Donald A. Smith, Kathleen Wyne, Michael Bush, Farhad Zangeneh, Yehuda Handelsman, David S.H. Bell, Zachary T. Bloomgarden, Eliot A. Brinton, Sergio Fazio, Vivian A. Fonseca, Alan J. Garber, George Grunberger, Chris K. Guerin, Paul S. Jellinger, Paul D. Rosenblit, Donald A. Smith, Kathleen Wyne & Michael H. Davidson. (2017) American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease. Endocrine Practice 23, pages 1-87.
Crossref
Crossref
Ching-Yun Wei, Ruben G. W. Quek, Guillermo Villa, Shravanthi R. Gandra, Carol A. Forbes, Steve Ryder, Nigel Armstrong, Sohan Deshpande, Steven Duffy, Jos Kleijnen & Peter Lindgren. (2016) A Systematic Review of Cardiovascular Outcomes-Based Cost-Effectiveness Analyses of Lipid-Lowering Therapies. PharmacoEconomics 35:3, pages 297-318.
Crossref
Crossref
Vivencio Barrios, Lisette Kaskens, José María Castellano, Juan Cosin-Sales, José Emilio Ruiz, Ilonka Zsolt, Valentín Fuster & Alfredo Gracia. (2017) Utilidad de un policomprimido cardiovascular en el tratamiento de pacientes en prevención secundaria en España: un estudio de coste-efectividad. Revista Española de Cardiología 70:1, pages 42-49.
Crossref
Crossref
Vivencio Barrios, Lisette Kaskens, José María Castellano, Juan Cosin-Sales, José Emilio Ruiz, Ilonka Zsolt, Valentín Fuster & Alfredo Gracia. (2017) Usefulness of a Cardiovascular Polypill in the Treatment of Secondary Prevention Patients in Spain: A Cost-effectiveness Study. Revista Española de Cardiología (English Edition) 70:1, pages 42-49.
Crossref
Crossref
Vasilios G. Athyros, Athanasios Papageorgiou, Valasia Athyrou & Asterios Karagiannis. (2017) Mortality reduction in patients treated with intensive lipid therapy vs usual care. Re: Zhao XQ, Phan BA, Davis J et al. Mortality reduction in patients treated with long-term intensive lipid therapy: 25-year follow-up of the Familial Atherosclerosis Treatment Study-Observational Study. J Clin Lipidol . 2016;10(5):1091-1097. Journal of Clinical Lipidology 11:1, pages 306-307.
Crossref
Crossref
Mieke L van Driel, Michael D Morledge, Robin Ulep, Johnathon P Shaffer, Philippa Davies & Richard Deichmann. (2016) Interventions to improve adherence to lipid-lowering medication. Cochrane Database of Systematic Reviews 2021:3.
Crossref
Crossref
S. Mitchell, S. Roso, M. Samuel & M. Pladevall-Vila. (2016) Unmet need in the hyperlipidaemia population with high risk of cardiovascular disease: a targeted literature review of observational studies. BMC Cardiovascular Disorders 16:1.
Crossref
Crossref
Yongbin Lu, Zhiyuan Cheng, Yaxue Zhao, Xiaoyu Chang, Cynthia Chan, Yana Bai & Ning Cheng. (2016) Efficacy and safety of long-term treatment with statins for coronary heart disease: A Bayesian network meta-analysis. Atherosclerosis 254, pages 215-227.
Crossref
Crossref
. (2016) Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials. The Lancet Diabetes & Endocrinology 4:10, pages 829-839.
Crossref
Crossref
Juan Wang, Dan Chen, Da-Bing Li, Xin Yu & Guo-Bing Shi. (2016) Comparison of the efficacy and safety of intensive-dose and standard-dose statin treatment for stroke prevention. Medicine 95:39, pages e4950.
Crossref
Crossref
Michel E. Bertrand, Charalambos Vlachopoulos & Jean-Jacques Mourad. (2016) Triple Combination Therapy for Global Cardiovascular Risk: Atorvastatin, Perindopril, and Amlodipine. American Journal of Cardiovascular Drugs 16:4, pages 241-253.
Crossref
Crossref
Raffaele De Caterina, Tanya Salvatore & Roberto Marchioli. (2016) All cholesterol-lowering interventions are expected to reduce stroke: Confirmatory data from IMPROVE-IT. Data in Brief 7, pages 1541-1550.
Crossref
Crossref
Thomas F. WhayneJr.Jr.. (2015) Defining the Role of PCSK9 Inhibitors in the Treatment of Hyperlipidemia. American Journal of Cardiovascular Drugs 16:2, pages 83-92.
Crossref
Crossref
André Miguel Ramos Travessa & Luiz Filipe de Menezes Falcão. (2016) Treatment of Heart Failure With Reduced Ejection Fraction—Recent Developments. American Journal of Therapeutics 23:2, pages e531-e549.
Crossref
Crossref
Harold E. Bays. (2016) A lipidologist perspective of global lipid guidelines and recommendations, part 2: Lipid treatment goals. Journal of Clinical Lipidology 10:2, pages 240-264.
Crossref
Crossref
Sudeepta Dandapat & Jennifer G. Robinson. (2016) Guidelines for Management of Hyperlipidemia: Implications for Treatment of Patients with Stroke Secondary to Atherosclerotic Disease. Current Neurology and Neuroscience Reports 16:3.
Crossref
Crossref
Terje R. Pedersen. (2016) The Success Story of LDL Cholesterol Lowering. Circulation Research 118:4, pages 721-731.
Crossref
Crossref
Johann Auer, Helmut Sinzinger, Barry Franklin & Robert Berent. (2014) Muscle- and skeletal-related side-effects of statins: tip of the iceberg?. European Journal of Preventive Cardiology 23:1, pages 88-110.
Crossref
Crossref
Thomas F. WhayneJrJr. (2014) Guideline Confusion for the Clinician. Angiology 67:1, pages 5-9.
Crossref
Crossref
Juan Tamargo, José M. Castellano & Valentín Fuster. (2016) WITHDRAWN: The fuster-CNIC-Ferrer cardiovascular polypill: A polypill for secondary cardiovascular prevention. International Journal of Cardiology.
Crossref
Crossref
Rafael Perera, Emily McFadden, Julie McLellan, Tom Lung, Philip Clarke, Teresa Pérez, Thomas Fanshawe, Andrew Dalton, Andrew Farmer, Paul Glasziou, Osamu Takahashi, John Stevens, Les Irwig, Jennifer Hirst, Sarah Stevens, Asuka Leslie, Sachiko Ohde, Gautam Deshpande, Kevin Urayama, Brian Shine & Richard Stevens. (2015) Optimal strategies for monitoring lipid levels in patients at risk or with cardiovascular disease: a systematic review with statistical and cost-effectiveness modelling. Health Technology Assessment 19:100, pages 1-402.
Crossref
Crossref
Michel P. Hermans, Evariste Bouenizabila, Daniel K. Amoussou-guenou, Sylvie A. Ahn & Michel F. Rousseau. (2015) Baseline diabetes as a way to predict CV outcomes in a lipid-modifying trial: a meta-analysis of 330,376 patients from 47 landmark studies. Cardiovascular Diabetology 14:1.
Crossref
Crossref
Juan Tamargo, José M. Castellano & Valentín Fuster. (2015) The Fuster-CNIC-Ferrer Cardiovascular Polypill: a polypill for secondary cardiovascular prevention. International Journal of Cardiology 201, pages S15-S23.
Crossref
Crossref
Yusuf Cetin Doganer, Kurt Angstman, James Rohrer & Stephen Merry. (2015) Impact of predictors upon the reduction of lipid parameters in family medicine practice. Sao Paulo Medical Journal 133:5, pages 428-434.
Crossref
Crossref
David Preiss, Ross T. Campbell, Heather M. Murray, Ian Ford, Chris J. Packard, Naveed Sattar, Kazem Rahimi, Helen M. Colhoun, David D. Waters, John C. LaRosa, Pierre Amarenco, Terje R. Pedersen, Matti J. Tikkanen, Michael J. Koren, Neil R. Poulter, Peter S. Sever, Paul M. Ridker, Jean G. MacFadyen, Scott D. Solomon, Barry R. Davis, Lara M. Simpson, Haruo Nakamura, Kyoichi Mizuno, Rosa M. Marfisi, Roberto Marchioli, Gianni Tognoni, Vasilios G. Athyros, Kausik K. Ray, Antonio M. Gotto, Michael B. Clearfield, John R. Downs & John J. McMurray. (2015) The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials. European Heart Journal 36:24, pages 1536-1546.
Crossref
Crossref
Vasilios G Athyros, Konstantinos Tziomalos, Niki Katsiki, Michael Doumas, Asterios Karagiannis & Dimitri P Mikhailidis. (2015) Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update. World Journal of Gastroenterology 21:22, pages 6820-6834.
Crossref
Crossref
Nadeem Qureshi, Rubin Minhas & Anthony S. Wierzbicki. (2015) Prioritizing health outcomes in a limited world. Current Opinion in Lipidology 26:3, pages 188-194.
Crossref
Crossref
Oleg Dolkart, Eyal Amar, Shiran Shapira, Sylvia Marmor, Eli L. Steinberg & Avi A. Weinbroum. (2015) Protective effects of rosuvastatin in a rat model of lung contusion: Stimulation of the cyclooxygenase 2–prostaglandin E-2 pathway. Surgery 157:5, pages 944-953.
Crossref
Crossref
Allan Sniderman. (2015) RETRACTED: The principles & practice of LDL lowering therapy. Journal of Indian College of Cardiology 5, pages S54-S57.
Crossref
Crossref
Jennifer A. Cann. 2015. The Nonhuman Primate in Nonclinical Drug Development and Safety Assessment. The Nonhuman Primate in Nonclinical Drug Development and Safety Assessment
257
277
.
Scott M. Grundy. 2015. Dyslipidemias. Dyslipidemias
313
327
.
Oleg Dolkart, Tamar Liron, Ofir Chechik, Dalia Somjen, Tamar Brosh, Eran Maman & Yankel Gabet. (2014) Statins Enhance Rotator Cuff Healing by Stimulating the COX2/PGE2/EP4 Pathway. The American Journal of Sports Medicine 42:12, pages 2869-2876.
Crossref
Crossref
. (2014) CardioPulse Articles. European Heart Journal 35:36, pages 2433-2440.
Crossref
Crossref
Neil J. Stone, Jennifer G. Robinson, Alice H. Lichtenstein, C. Noel Bairey Merz, Conrad B. Blum, Robert H. Eckel, Anne C. Goldberg, David Gordon, Daniel Levy, Donald M. Lloyd-Jones, Patrick McBride, J. Sanford Schwartz, Susan T. Shero, Sidney C. SmithJr.Jr., Karol Watson & Peter W.F. Wilson. (2014) 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. Journal of the American College of Cardiology 63:25, pages 2889-2934.
Crossref
Crossref
Neil J. Stone, Jennifer G. Robinson, Alice H. Lichtenstein, C. Noel Bairey Merz, Conrad B. Blum, Robert H. Eckel, Anne C. Goldberg, David Gordon, Daniel Levy, Donald M. Lloyd-Jones, Patrick McBride, J. Sanford Schwartz, Susan T. Shero, Sidney C. SmithJrJr, Karol Watson & Peter W. F. Wilson. (2014) 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. Circulation 129:25_suppl_2.
Crossref
Crossref
Scott L. Charland & Eric J. Stanek. (2014) Sigmoidal Maximal Effect Modeling of Low-Density Lipoprotein Cholesterol Concentration and Annual Incidence of Coronary Heart Disease Events in Secondary Prevention Trials. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 34:5, pages 452-463.
Crossref
Crossref
Vasilios G. Athyros, Niki Katsiki & Asterios Karagiannis. (2013) Treating Heart Failure With Preserved Ejection Fraction. Angiology 65:4, pages 328-329.
Crossref
Crossref
Wen Wang & Bo Zhang. (2014) Statins for the Prevention of Stroke: A Meta-Analysis of Randomized Controlled Trials. PLoS ONE 9:3, pages e92388.
Crossref
Crossref
Thomas F. WhayneJrJr. (2013) Low-Density Lipoprotein Cholesterol Targeting. Angiology 65:3, pages 263-264.
Crossref
Crossref
Ashish Sood, Eelco Kappe & Stefan Stremersch. (2014) The commercial contribution of clinical studies for pharmaceutical drugs. International Journal of Research in Marketing 31:1, pages 65-77.
Crossref
Crossref
Satoshi Okumura, Masaki Sakakibara, Ryo Hayashida, Yasushi Jinno, Akihito Tanaka, Koji Okada, Mutsuharu Hayashi, Hideki Ishii & Toyoaki Murohara. (2013) Accelerated decline in renal function after acute myocardial infarction in patients with high low-density lipoprotein-cholesterol to high-density lipoprotein-cholesterol ratio. Heart and Vessels 29:1, pages 7-14.
Crossref
Crossref
Faruk Turgut, Ihsan Ustun & Cumali Gokce. 2014. Dyslipidemias in Kidney Disease. Dyslipidemias in Kidney Disease
45
65
.
Hisato Takagi & Takuya Umemoto. (2013) Low-density lipoprotein-dependent and independent effects of statins on prevention of major coronary events: Meta-regression of randomized placebo-controlled trials. International Journal of Cardiology 168:5, pages 4850-4853.
Crossref
Crossref
Matti J. Tikkanen, Rana Fayyad, Ole Faergeman, Anders G. Olsson, Chuan-Chuan Wun, Rachel Laskey, John J. Kastelein, Ingar Holme & Terje R. Pedersen. (2013) Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels. International Journal of Cardiology 168:4, pages 3846-3852.
Crossref
Crossref
Thomas F. WhayneJrJr. (2012) Assessment of Low-Density Lipoprotein Targets. Angiology 64:6, pages 411-416.
Crossref
Crossref
Anthony S. Wierzbicki. (2013) Doubling up: maximising statin therapy as opposed to adding other drugs for cardiovascular disease prevention. International Journal of Clinical Practice 67:5, pages 391-393.
Crossref
Crossref
Bernadette A. Tumanan-Mendoza & Victor L. Mendoza. (2013) Economic Evaluation of Lipid-Lowering Therapy in the Secondary Prevention Setting in the Philippines. Value in Health Regional Issues 2:1, pages 13-20.
Crossref
Crossref
Eberhard Standl. (2012) Statins and beyond: Concurrent strategies for prevention of cardiovascular disease in patients with type 2 diabetes. Diabetes and Vascular Disease Research 10:2, pages 99-114.
Crossref
Crossref
Michael S Kostapanos. (2013) Current role of fenofibrate in the prevention and management of non-alcoholic fatty liver disease. World Journal of Hepatology 5:9, pages 470.
Crossref
Crossref
Hong Sun, Yang Yuan & Zi-Lin Sun. (2013) Cholesterol Contributes to Diabetic Nephropathy through SCAP-SREBP-2 Pathway. International Journal of Endocrinology 2013, pages 1-8.
Crossref
Crossref
Deepa Jagtap, Carol A. Rosenberg, Lisa W. Martin, Mary Pettinger, Janardan Khandekar, Dorothy Lane, Ira Ockene & Michael S. Simon. (2012) Prospective analysis of association between use of statins and melanoma risk in the Women's Health Initiative. Cancer 118:20, pages 5124-5131.
Crossref
Crossref
Vasilios G. Athyros, Asterios Karagiannis, Niki Katsiki & Dimitri P. Mikhailidis. (2012) Relation of Improvement in Glomerular Filtration Rate With Atorvastatin to Reductions in Heart Failure Morbidity. The American Journal of Cardiology 110:5, pages 763.
Crossref
Crossref
James S. McKinneyWilliam J. Kostis. (2012) Statin Therapy and the Risk of Intracerebral Hemorrhage. Stroke 43:8, pages 2149-2156.
Crossref
Crossref
. (2012) The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. The Lancet 380:9841, pages 581-590.
Crossref
Crossref
Kiyoshi Kikuchi, Hisaaki Uchikado, Motohiro Morioka, Yoshinaka Murai & Eiichiro Tanaka. (2012) Clinical Neuroprotective Drugs for Treatment and Prevention of Stroke. International Journal of Molecular Sciences 13:6, pages 7739-7761.
Crossref
Crossref
Paul S. Jellinger, Donald A. Smith, Adi E. Mehta, Om Ganda, Yehuda Handelsman, Helena W. Rodbard, Mark D. Shepherd & John A. Seibel. (2012) American Association of Clinical Endocrinologists' Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis. Endocrine Practice 18, pages 1-78.
Crossref
Crossref
Goodarz Danaei, Mohammad Tavakkoli & Miguel A. Hernán. (2012) Bias in Observational Studies of Prevalent Users: Lessons for Comparative Effectiveness Research From a Meta-Analysis of Statins. American Journal of Epidemiology 175:4, pages 250-262.
Crossref
Crossref
M. Alberton, P. Wu, E. Druyts, M. Briel & E. J. Mills. (2012) Adverse events associated with individual statin treatments for cardiovascular disease: an indirect comparison meta-analysis. QJM: An International Journal of Medicine 105:2, pages 145-157.
Crossref
Crossref
. (2012) Lack of Effect of Lowering LDL Cholesterol on Cancer: Meta-Analysis of Individual Data from 175,000 People in 27 Randomised Trials of Statin Therapy. PLoS ONE 7:1, pages e29849.
Crossref
Crossref
Pratik Bhattacharya & Seemant Chaturvedi. (2011) Dyslipidemia Management. CONTINUUM: Lifelong Learning in Neurology 17, pages 1242-1254.
Crossref
Crossref
Daniel G. HackamMark WoodwardL. Kristin NewbyDeepak L. BhattMingyuan ShaoEric E. SmithAllan DonnerMuhammad MamdaniJames D. DouketisHisatomi ArimaJohn ChalmersStephen MacMahonDavid L. TirschwellBruce M. PsatyCheryl D. BushnellMaria I. AguilarDan J. CapampanganDavid J. WerringPaola De RangoAnand ViswanathanNicolas DanchinChing-Lan ChengYea-Huei Kao YangB. Marianne VerdelMei-Shu LaiJames KennedyShinichiro UchiyamaTakenori YamaguchiYasuo IkedaMarko Mrkobrada. (2011) Statins and Intracerebral Hemorrhage. Circulation 124:20, pages 2233-2242.
Crossref
Crossref
Hyung-Min Kwon, Jae-Sung Lim, Hong-Kyun Park & Yong-Seok Lee. (2011) Hypertriglyceridemia as a possible predictor of early neurological deterioration in acute lacunar stroke. Journal of the Neurological Sciences 309:1-2, pages 128-130.
Crossref
Crossref
Michael Grabner, Wallace Johnson, Abdulla M. Abdulhalim, Andreas Kuznik & C. Daniel Mullins. (2011) The Value of Atorvastatin Over the Product Life Cycle in the United States. Clinical Therapeutics 33:10, pages 1433-1443.
Crossref
Crossref
Mihály Medvegy, G. Simonyi, N. Medvegy & Zs. Pécsvárady. (2011) Non-ST elevation myocardial infarction: A new pathophysiological concept could solve the contradiction between accepted cause and clinical observations. Acta Physiologica Hungarica 98:3, pages 252-261.
Crossref
Crossref
V. V. Belov, S. Yu. Bezdol’nova & I. I. Dolgushin. (2011) Dynamics of clinical, functional, and immune parameters in patients with myocardial infarction and early fluvastatin administration. Cardiovascular Therapy and Prevention 10:4, pages 52-58.
Crossref
Crossref
M Tanaka. (2011) Beneficial Effect of Atorvastatin on Renal Function in Patients with Type 2 Diabetes. Journal of International Medical Research 39:4, pages 1504-1512.
Crossref
Crossref
Patrizia Berto & S. Lopatriello. (2013) Efficacia clinica e costo-efficacia di atorvastatina a elevati dosaggi nella prevenzione degli eventi cardiocerebrovascolariClinical efficacy and cost-effectiveness of high-dose atorvastatin for the secondary prevention of cardiocerebrovascular events. Giornale Italiano di Health Technology Assessment 4:1, pages 17-31.
Crossref
Crossref
M. C. S. Wong, J. Y. Jiang & S. M. Griffiths. (2011) Adherence to lipid-lowering agents among 11,042 patients in clinical practice. International Journal of Clinical Practice 65:7, pages 741-748.
Crossref
Crossref
Hisato Takagi & Takuya Umemoto. (2011) Reduction in coronary heart disease with atorvastatin independent of low-density lipoprotein cholesterol. International Journal of Cardiology 149:2, pages 267-269.
Crossref
Crossref
Antonio Pérez, Cintia González Blanco, Miguel Ángel Hernández-Presa & José Chaves. (2011) Estrategia de tratamiento de la dislipemia y consecución de objetivos en la población española con diabetes tipo 2 sin enfermedad cardiovascular. Endocrinología y Nutrición 58:6, pages 283-290.
Crossref
Crossref
Bernhard Föger. (2011) Lipid lowering therapy in type 2 diabetesBehandlung mit Lipidsenkern bei Typ-2-Diabetes. Wiener Medizinische Wochenschrift 161:11-12, pages 289-296.
Crossref
Crossref
D. John Betteridge. (2011) Lipid control in patients with diabetes mellitus. Nature Reviews Cardiology 8:5, pages 278-290.
Crossref
Crossref
A. S. Wierzbicki. (2011) Statin wars: efficacy vs. cost. International Journal of Clinical Practice 65:2, pages 108-111.
Crossref
Crossref
E. J. Mills, P. WU, G. Chong, I. Ghement, S. Singh, E. A. Akl, O. Eyawo, G. Guyatt, O. Berwanger & M. Briel. (2010) Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170 255 patients from 76 randomized trials. QJM 104:2, pages 109-124.
Crossref
Crossref
Antonio Pérez, Cintia González Blanco, Miguel Ángel Hernández-Presa & José Chaves. (2011) Therapeutic approach to dyslipidemia and goal achievement in a Spanish population with type 2 diabetes without cardiovascular disease. Endocrinología y Nutrición (English Edition) 58:6, pages 283-290.
Crossref
Crossref
Raza H. Orakzai, Chrisandra L. Shufelt, Leslee J. Shaw & C. Noel Bairey Merz. 2011. Preventive Cardiology: Companion to Braunwald's Heart Disease. Preventive Cardiology: Companion to Braunwald's Heart Disease
398
414
.
Niels Engberding & Nanette K. Wenger. 2011. Atlas of Atherosclerosis and Metabolic Syndrome. Atlas of Atherosclerosis and Metabolic Syndrome
253
299
.
Vasilios G Athyros, Konstantinos Tziomalos, Thomas D Gossios, Theodora Griva, Panagiotis Anagnostis, Konstantinos Kargiotis, Efstathios D Pagourelias, Eleni Theocharidou, Asterios Karagiannis & Dimitri P Mikhailidis. (2010) Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. The Lancet 376:9756, pages 1916-1922.
Crossref
Crossref
. (2010) Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. The Lancet 376:9753, pages 1670-1681.
Crossref
Crossref
Timm Bauer, Anselm K. Gitt, Claus Jünger, Ralf Zahn, Oliver Koeth, Frank Towae, Arne K. Schwarz, Kurt Bestehorn, Jochen Senges & Uwe Zeymer. (2010) Guideline-recommended secondary prevention drug therapy after acute myocardial infarction: predictors and outcomes of nonadherence. European Journal of Cardiovascular Prevention & Rehabilitation 17:5, pages 576-581.
Crossref
Crossref
Emina Aleksić, Radmila Stamenković, Dragan Đorđević, Gordana Lazarević, Duško Vulić & Ivan Tasić. (2010) Prognostic factors in patients who have survived myocardial infarction. Open Medicine 5:4, pages 513-519.
Crossref
Crossref
Richard Lowrie, Jill Morrison & Alex McConnachie. (2010) A cluster randomised controlled trial of pharmacist led Statin Outreach Support (SOS) in primary care: Design and baseline characteristics. Contemporary Clinical Trials 31:4, pages 303-311.
Crossref
Crossref
Jorge R. Kizer, Christopher Madias, Brian Wilner, Carl J. Vaughan, Alvin I. Mushlin, Paula Trushin, Antonio M. GottoJr.Jr. & Richard C. Pasternak. (2010) Relation of Different Measures of Low-Density Lipoprotein Cholesterol to Risk of Coronary Artery Disease and Death in a Meta-Regression Analysis of Large-Scale Trials of Statin Therapy. The American Journal of Cardiology 105:9, pages 1289-1296.
Crossref
Crossref
Vasilios G. Athyros, Asterios Karagiannis & Dimitri P. Mikhailidis. (2010) Statins and Heart Failure. Journal of the American College of Cardiology 55:15, pages 1644-1645.
Crossref
Crossref
Angela Schedlbauer, Philippa Davies & Tom Fahey. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
Naveed Sattar, David Preiss, Heather M Murray, Paul Welsh, Brendan M Buckley, Anton JM de Craen, Sreenivasa Rao Kondapally Seshasai, John J McMurray, Dilys J Freeman, J Wouter Jukema, Peter W Macfarlane, Chris J Packard, David J Stott, Rudi G Westendorp, James Shepherd, Barry R Davis, Sara L Pressel, Roberto Marchioli, Rosa Maria Marfisi, Aldo P Maggioni, Luigi Tavazzi, Gianni Tognoni, John Kjekshus, Terje R Pedersen, Thomas J Cook, Antonio M Gotto, Michael B Clearfield, John R Downs, Haruo Nakamura, Yasuo Ohashi, Kyoichi Mizuno, Kausik K Ray & Ian Ford. (2010) Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. The Lancet 375:9716, pages 735-742.
Crossref
Crossref
Kiyoko Uno & Stephen J. Nicholls. (2010) Statin Effects on Both Low-Density Lipoproteins and High-Density Lipoproteins: Is There a Dual Benefit?. Current Atherosclerosis Reports 12:1, pages 14-19.
Crossref
Crossref
Malcolm Law. 2009. Evidence‐Based Cardiology. Evidence‐Based Cardiology
138
146
.
Theodoros I. Kassimatis & Panagiotis A. Konstantinopoulos. (2009) The role of statins in chronic kidney disease (CKD): Friend or foe?. Pharmacology & Therapeutics 122:3, pages 312-323.
Crossref
Crossref
Displaying 200 of 388 citing articles. Use the download link below to view the full list of citing articles.
Download full citations list